- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05750953
Nurse-assisted Intervention "eHealth@ Hospital -2-home" (Ehealth@H2H)
December 4, 2023 updated by: University of Stavanger
Project Title: Nurse Assisted eHealth Service From Hospital to Home: Ameliorating Burden of Treatment Among Patients With Non-Communicable Diseases
A randomized controlled trial with non-communicable disease patients from two medical hospitals in Norway will be recruited prior to hospital discharge.
The intervention group will participate in a 42-day nurse-assisted eHealth intervention "eHealth@ Hospital-2-Home".
The intervention includes monitoring the patient's vital signs, self-reports of symptoms, health and well-being, communication between the patients and a Nurse Navigator in the hospital, and access to information about illness and health resources.
Study Overview
Status
Recruiting
Intervention / Treatment
Detailed Description
Heart failure (HF) and colon-rectal cancer (CRC) are two non-communicable diseases (NCDs) prone to a high rate of hospital admissions and re-admissions, and complex health care needs.
For many patients with HF and CRC, self-management following hospitalization can be a challenge, and they may leave the hospital unprepared for self-managing their disease at home.
The randomized controlled trial with NCD patients from two medical hospitals in Norway.
Patients will be recruited before hospital discharge.
The intervention group will participate in a 42-day nurse-assisted intervention ""eHealth@ Hospital-2-Home"".
The intervention includes monitoring of patients' vital signs, self-reports of symptoms, health and well-being, communication between the patients and a Nurse Navigator in the hospital, and access to information about illness and health resources.
The control group will receive care as usual.
Data collection will take place before the intervention (baseline), at the end of the intervention (post-1), and 6 months after baseline (post-2).
Data will be according to intention to treat principles.
Qualitative data will be analyzed using thematic analysis.
Study Type
Interventional
Enrollment (Estimated)
240
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Anne Marie L Husebø, PhD
- Phone Number: 004799262805
- Email: anne.m.husebo@uis.no
Study Locations
-
-
Rogaland
-
Stavanger, Rogaland, Norway, 4036
- Recruiting
- Anne Marie Lunde Husebø
-
Contact:
- Svein Scheie, MD, PhD
- Email: svein.skeie@sus.no
-
Contact:
- Marianne Storm, PhD
- Phone Number: Storm 004748133750
- Email: marianne.storm@uis.no
-
Sub-Investigator:
- Marianne Storm, PhD
-
Principal Investigator:
- Ingvild M Morken, PhD
-
Principal Investigator:
- Anne Marie L Husebø, PhD
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- All participants: symptomatic HF or surgically treated for either colon or rectal cancer (Colon-Rectal Cancer Duke's class 1-3, curative), able to speak and write Norwegian
Exclusion Criteria:
- Heart failure population: patient is on a waiting list for a heart transplant, requires a Left Assist Ventricular Device (LVAD), and has a life expectancy <6 months
- Colon-rectal cancer population: metastatic cancer, Surgical Complication Score > 3, and acute medical crisis.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: eHealth@H-2-H
The intervention group will participate in a 42-day nurse-assisted intervention "eHealth@ Hospital-2-Home".
The intervention includes monitoring of vital signs, self-reports of symptoms, health and well-being, access to information about illness and health resources , and communication between the patients and a hospital-based Nurse Navigator.
|
At hospital discharge, the intervention group will receive a wireless, portable personal computer system (i.e., IPAD) that includes the eHealth application MyDignio supplied by a certified m-Health company.
MyDignio app is linked to monitoring devices by Bluetooth for each patient to daily and weekly measure clinical measures such as blood pressure, pulse, temperature, and weight, and self-reported symptoms and well-being, and daily report clinical measurements to the Nurse Navigators employed in the two hospitals.
The patients will receive training from the nurses on how to log on and use the MyDignio app and the monitoring devices.
Telephone contact details including information about how to access technical support will be provided to each study participant shortly following discharge.
Other Names:
|
No Intervention: Care as usual
The control group will receive care as usual
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient confidence in self-management activities.
Time Frame: Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in the patient's confidence in self-management of heart failure or colon-rectal cancer disease between baseline and post-1 and 2 will be measured by the 6 items questionnaire Self-Efficacy for Managing Chronic Disease".
Values: 1-10.
A higher score mean a better outcome.
|
Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in heart failure self-care behavior
Time Frame: Baseline (at discharge), post-1, (42 days following baseline, at the end of the intervention) and post-2 (6 months after baseline)
|
Change in heart failure patients' self-care behavior between baseline and post-1 and 2 will be measured by use of the European Heart Failure Self-care Behavior Scale.
Value: 1-5.
Higher score mean worse outcome.
|
Baseline (at discharge), post-1, (42 days following baseline, at the end of the intervention) and post-2 (6 months after baseline)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in patient experience with treatment and self-management.
Time Frame: Baseline (at discharge), post-1(42 days following baseline, at the end of the intervention) , and post-2 (6 months after baseline)
|
Change in the patient's experience with treatment and self-management of heart failure and colon-rectal cancer between baseline and post-1 and 2 will be measured by the questionnaire "Patient Experience with Treatment and Self-management" with four dimensions of Medical information (Values:1-6); Monitoring health (Values: 1-6); Medications (Values 1- 5); Medical appointments (Values: 1-5).
Higher scores means a worse outcome.
|
Baseline (at discharge), post-1(42 days following baseline, at the end of the intervention) , and post-2 (6 months after baseline)
|
Change in patient experience of health condition and how it affects daily life.
Time Frame: Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in the patient's Health Related Quality of Life between baseline and post 1 and 2 will be measured with the European Quality of life 5 Dimensions -5 Levels questionnaire.
Values: 1-5, were higher scores mean worse outcome, and on a visual analog scale from 0-100, were higher scores mean better outcome.
|
Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in patient experience of constructive support from healthcare personnel
Time Frame: Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in perceived support between baseline and post-1 and 2 will be measured using 12 items on constructive support.
Values: 1-5-point.
Higher score mean worse outcome.
|
Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in patient experience of shared decision-making.
Time Frame: Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in the patient's experience of shared decision-making between baseline and post-1 and 2 will be measured using the 3 items questionnaire "CollaboRATE" Value: 0-10.
Higher score mean better outcome.
|
Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in health care utilization
Time Frame: Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Change in health care utilization between baseline and post-1 and 2 will be measured using patients' self-reports of number of visits to the primary healthcare service (i.e., General Practitioner, municipal emergency department) and/or the specialist healthcare service (i.e., outpatient clinic).
Fewer visits mean better outcome.
|
Baseline (at discharge), post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline)
|
Days alive and out of hospital
Time Frame: Post-2 (6 months after baseline)
|
Days alive and out of hospital will be measured by patient's self-report against data from hospital records, and calculated by subtracting number of days spent away from home due to heart failure or colon-rectal cancer related hospitalization from the day of the first reporting in the patient application and the six months following (post 2).
|
Post-2 (6 months after baseline)
|
Number of 30 days readmission for heart failure or colon-rectal cancer related incidents
Time Frame: Post-1 (42 days following baseline, at the end of the intervention).
|
Numbers of 30-days readmission for Heart failure or Colon-rectal cancer related incidents will be collected from the electronic health care record system in the hospital.
|
Post-1 (42 days following baseline, at the end of the intervention).
|
Number of 90 days readmission for heart failure or colon-rectal cancer related incidents
Time Frame: Post-2 (6 months following baseline)
|
Numbers of 30-days readmission for heart failure or colon-rectal cancer related incidents will be collected from the electronic health care record system in the hospital.
|
Post-2 (6 months following baseline)
|
Number of 12 months readmission for heart failure or colon-rectal cancer related incidents
Time Frame: Post-3 (12 months following baseline)
|
Numbers of 12-months readmission for heart failure or colon-rectal cancer related incidents will be collected from the electronic health care record system in the hospital.
|
Post-3 (12 months following baseline)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in medication adherence in heart failure patients
Time Frame: Post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline).
|
Change in medication adherence will be measures using the Medication Adherence Reasons Scale-5 (MARS -5) containing 5 items.
|
Post-1 (42 days following baseline, at the end of the intervention), and post-2 (6 months after baseline).
|
Patient satisfaction with using the technology.
Time Frame: Post-1 (42 days following baseline, at the end of the intervention)
|
Patient satisfaction with using the technology will be measured by the Post-Study System Usability Questionnaire.
Values: 1-7.
Higher score mean worse outcome.
|
Post-1 (42 days following baseline, at the end of the intervention)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Anne Marie Husebø, PhD, University of Stavanger
- Principal Investigator: Ingvild M Morken, PhD, University of Stavanger
- Principal Investigator: Marianne Storm, PhD, University of Stavanger
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
May 5, 2023
Primary Completion (Estimated)
June 30, 2024
Study Completion (Estimated)
December 31, 2024
Study Registration Dates
First Submitted
November 2, 2022
First Submitted That Met QC Criteria
February 27, 2023
First Posted (Actual)
March 2, 2023
Study Record Updates
Last Update Posted (Estimated)
December 5, 2023
Last Update Submitted That Met QC Criteria
December 4, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 301472
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Heart Failure
-
Tufts Medical CenterMetro West Medical CenterCompletedCongestive Heart Failure | Diastolic Heart Failure | Systolic Heart FailureUnited States
-
Abbott Medical DevicesCompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure NYHA Class II | Heart Failure NYHA Class III | Heart Failure With Reduced Ejection Fraction | Heart Failure NYHA Class IV | Heart Failure With Normal Ejection Fraction | Heart Failure; With Decompensation | Heart Failure...United States, Canada
-
Manipal UniversityUnknownHeart Failure | Decompensated Heart Failure | Acute Heart Failure | Diastolic Heart Failure | Systolic Heart FailureIndia
-
VA Eastern Colorado Health Care SystemNational Institute on Aging (NIA)CompletedHeart Failure | Heart Failure, Diastolic | Heart Failure, Systolic | Heart Failure With Reduced Ejection Fraction | Heart Failure With Preserved Ejection Fraction | Heart Failure; With Decompensation | Heart Failure,Congestive | Heart Failure AcuteUnited States
-
University Hospital, MontpellierCompletedHeart Failure | Diastolic Heart Failure | Systolic Heart Failure Stage CFrance
-
Wake Forest UniversityCompletedHeart Failure, Congestive | Heart Failure With Preserved Ejection Fraction
-
Lancaster General HospitalLouise von Hess Medical Research InstituteEnrolling by invitationDiastolic Heart FailureUnited States
-
Wake Forest UniversityNational Institute on Aging (NIA)CompletedHeart Failure, Congestive | Diastolic Heart FailureUnited States
-
Giresun UniversityIstanbul University - Cerrahpasa (IUC)RecruitingHeart Failure | Diastolic Heart Failure | Systolic Heart FailureTurkey
-
US Department of Veterans AffairsCompleted
Clinical Trials on eHealth@Hospital-2-Home
-
National University Health System, SingaporeNational University of SingaporeCompleted
-
Brigham and Women's HospitalRecruitingBariatric Surgery Candidate | Bariatric Sleeve Gastrectomy | Home HospitalUnited States
-
Stiftelsen Stockholms SjukhemKarolinska InstitutetRecruitingPhysical Activity | Parkinson Disease | Gait Disorders, Neurologic | eHealthSweden
-
Brigham and Women's HospitalThe Thompson Family Foundation IncCompletedHeart Failure | Infections | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Asthma | Anticoagulation | Gout Flare | Hypertensive Urgency | Atrial Fibrillation Rapid | Diabetes and Its Complications | End of Life/Desires Only Medical ManagementUnited States, Canada
-
Brigham and Women's HospitalRxFoundationCompletedHeart Failure | Chronic Kidney Diseases | Chronic Obstructive Pulmonary Disease | Asthma | Infection | Gout Flare | Hypertensive Urgency | Anticoagulants; Increased | Atrial Fibrillation RapidUnited States
-
Chang Gung Memorial HospitalNational Science Council, Taiwan; National Health Research Institutes, TaiwanCompletedCerebrovascular AccidentsTaiwan
-
Nordsjaellands HospitalUniversity of Southern Denmark; Innovation Fund DenmarkRecruiting
-
Defactum, Central Denmark RegionViborg Regional Hospital; Interdisciplinary Centre for Organizational Architecture... and other collaboratorsRecruiting
-
Princess Margaret Hospital for ChildrenCompleted
-
Azienda Ospedaliera San Giovanni BattistaCompletedCOPD Exacerbation